Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, and Soupline to a range of traditional and eCommerce retailers, wholesalers, and distributors. It includes pharmaceutical products for dentists and other oral health professionals. Its Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Colgate-Palmolive Company

Colgate-Palmolive Company CL is expected to register a bottom-line decline when it reports third-quarter 2025 results on Oct. 31, before the opening bell. The Zacks Consensus Estimate for third-quarter revenues is pegged at $5.1 billion, indicating growth of 2% from the year-ago quarter’s reported figure.
The consensus estimate for CL’s earnings is pegged at 89 cents per share and is expected to decline 2.2% year over year. The Zacks Consensus Estimate for earnings for the quarter has moved down by a penny in the past seven days.
In the last reported quarter, the company's earnings beat the consensus estimate by 3.4%. It has delivered an earnings surprise of 3.7%, on average, in the trailing four quarters.
Colgate-Palmolive Company Price and EPS Surprise
What the Zacks Model Unveils for CL Stock
Our proven model does not conclusively predict an earnings beat for Colgate this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
Colgate currently has an Earnings ESP of -0.61% and a Zacks Rank of 4 (Sell).
Key Aspects to Note Ahead of CL’s Q3 Results
Colgate’s third-quarter performance is expected to have benefited from solid business momentum, supported by pricing, funding-the-growth initiative and other productivity initiatives. The company’s idea of delivering balanced organic sales growth, driven by improvements in all categories and divisions, and volume and pricing gains, has been driving its performance. CL’s brand strength, coupled with its focus on innovation, premiumization and digital transformation, is expected to have driven its performance in the to-be-reported quarter.
Colgate’s focus on science-based, value-added innovation — exemplified by the relaunch of Colgate Total, Colgate Miracle Repair serum and Hill’s therapeutic lines — is supporting category growth and brand penetration.
Our model predicts sales growth of 2.9% for third-quarter 2025, with organic sales growth of 2.1%. We expect the volume decline of 0.1% to be largely offset by pricing gains of 2.2% for the third quarter. Our model predicts a 1.5% rise in sales in Latin America, 8% growth in Europe, a 1% increase in Asia Pacific, an 8.5% increase in Africa/Eurasia and a 4.2% rise in Pet Nutrition. This is expected to be partly offset by a 1.1% decline in North America.
The company has been delivering a sequential rise in the gross margin for the past few quarters, driven by continued strong pricing, benefits from revenue growth management initiatives, strength in the funding-the-growth program and other productivity initiatives. Continued gains from these initiatives are expected to have led to a gross margin expansion in the to-be-reported quarter. Our model predicts sequential gross margin growth of 60 bps to 60.7% for the third quarter of 2025.
However, Colgate’s third-quarter 2025 performance is likely to have encountered continued headwinds from a combination of inflationary pressures, foreign currency fluctuations and soft performance across key regions. Markets like Latin America, which previously experienced significant pressure from currency devaluation despite growth in pricing and volume, have been vulnerable. These foreign exchange headwinds are expected to have continued eroding sales on a reported basis in the quarter under review.
On the last reported quarter’searnings call management anticipated the uncertainty and volatility across the global markets and the impacts of tariffs to remain challenging in the quarters ahead. In addition, consumer uncertainty and a slowdown in category pricing remain headwinds.
CL’s Price Performance & Valuation
The recent market movements show that Colgate’s shares have lost 10.4% in the past three months compared with the industry's 5.1% decline.
From the valuation standpoint, CL trades at a forward 12-month P/E multiple of 20.18X, exceeding the industry average of 19.05X and below the S&P 500’s average of 23.69X. Its valuation appears quite pricey.
Image Source: Zacks Investment Research
Stocks With the Favorable Combination
Here are some companies that, according to our model, have the right combination of elements to beat on earnings this reporting cycle.
Vital Farms VITL currently has an Earnings ESP of +8.84% and flaunts a Zacks Rank of 1. VITL is anticipated to register increases in its top and bottom lines when it reports third-quarter 2025 results. The Zacks Consensus Estimate for Vital Farms’ quarterly revenues is pegged at $191 million, indicating growth of 31.7% from the figure reported in the prior-year quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
The consensus estimate for Vital Farms’ bottom line has been unchanged in the past 30 days at 29 cents per share. This implies a surge of 81.3% from the year-ago quarter’s reported figure. VITL delivered an earnings beat of 35.8%, on average, in the trailing four quarters.
The Estee Lauder Companies EL has an Earnings ESP of +15.65% and a Zacks Rank of 3 at present. EL is likely to register growth in its top and bottom lines when it releases first-quarter fiscal 2026 results. The Zacks Consensus Estimate for its quarterly revenues is pegged at $3.4 billion, which implies growth of 0.6% from the figure in the prior-year quarter.
The consensus estimate for Estee Lauder’s bottom line has moved up by a penny to 16 cents per share in the past seven days. The estimate indicates 14.3% growth from the year-ago quarter’s actual. EL delivered an earnings surprise of 71.5%, on average, in the trailing four quarters.
Monster Beverage MNST currently has an Earnings ESP of +0.82% and a Zacks Rank of 3. The company is likely to register increases in the top and bottom lines when it reports third-quarter 2025 numbers. The Zacks Consensus Estimate for quarterly earnings per share is pegged at 48 cents, suggesting a 20% growth from the year-ago period’s reported number. The consensus mark has been unchanged in the past 30 days.
The consensus estimate for Monster Beverage’s quarterly revenues is pegged at $2.1 billion, which indicates growth of 11.9% from the prior-year quarter’s actual. MNST has a trailing four-quarter earnings surprise of 0.2%, on average.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Colgate's Pre-Q3 Earnings: Will Pricing Actions Offset Cost Headwinds?

Wall Street expects a year-over-year decline in earnings on higher revenues when Colgate-Palmolive (CL) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 31. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This consumer products maker is expected to post quarterly earnings of $0.89 per share in its upcoming report, which represents a year-over-year change of -2.2%.
Revenues are expected to be $5.13 billion, up 2% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0.29% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Colgate-Palmolive?
For Colgate-Palmolive, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.61%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Colgate-Palmolive will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Colgate-Palmolive would post earnings of $0.89 per share when it actually produced earnings of $0.92, delivering a surprise of +3.37%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Colgate-Palmolive doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry Player
Kimberly-Clark (KMB), another stock in the Zacks Consumer Products - Staples industry, is expected to report earnings per share of $1.45 for the quarter ended September 2025. This estimate points to a year-over-year change of -20.8%. Revenues for the quarter are expected to be $4.08 billion, down 17.6% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Kimberly-Clark has been revised 7.1% down to the current level. Nevertheless, the company now has an Earnings ESP of -4.99%, reflecting a lower Most Accurate Estimate.
When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that Kimberly-Clark will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Should You Invest in Colgate-Palmolive Company (CL)?
Before you invest in Colgate-Palmolive Company (CL), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Analysts Estimate Colgate-Palmolive (CL) to Report a Decline in Earnings: What to Look Out for

Investors in Colgate-Palmolive Co. (Symbol: CL) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CL options chain for the new December 5th contracts and identified one put and one call contract of particular interest.
The put contract at the $77.00 strike price has a current bid of 5 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $77.00, but will also collect the premium, putting the cost basis of the shares at $76.95 (before broker commissions). To an investor already interested in purchasing shares of CL, that could represent an attractive alternative to paying $78.16/share today.
Because the $77.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 60%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.06% return on the cash commitment, or 0.55% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Colgate-Palmolive Co., and highlighting in green where the $77.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $80.00 strike price has a current bid of 40 cents. If an investor was to purchase shares of CL stock at the current price level of $78.16/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $80.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 2.87% if the stock gets called away at the December 5th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if CL shares really soar, which is why looking at the trailing twelve month trading history for Colgate-Palmolive Co., as well as studying the business fundamentals becomes important. Below is a chart showing CL's trailing twelve month trading history, with the $80.00 strike highlighted in red:
Considering the fact that the $80.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 57%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.51% boost of extra return to the investor, or 4.34% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 24%, while the implied volatility in the call contract example is 28%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 250 trading day closing values as well as today's price of $78.16) to be 21%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Also see:
Top High Dividend Yield Stocks
PEO Historical Stock Prices
Top Ten Hedge Funds Holding PXLG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CL December 5th Options Begin Trading

Below is Validea's guru fundamental report for COLGATE-PALMOLIVE CO (CL). Of the 22 guru strategies we follow, CL rates highest using our Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.
COLGATE-PALMOLIVE CO (CL) is a large-cap growth stock in the Personal & Household Prods. industry. The rating using this strategy is 68% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of COLGATE-PALMOLIVE CO
More Information on Warren Buffett
About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. As the chairman of Berkshire Hathaway, Buffett has consistently outperformed the S&P 500 for decades, and in the process has become one of the world's richest men. (Forbes puts his net worth at $37 billion.) Despite his fortune, Buffett is known for living a modest lifestyle, by billionaire standards. His primary residence remains the gray stucco Nebraska home he purchased for $31,500 nearly 50 years ago, according to Forbes, and his folksy Midwestern manner and penchant for simple pleasures -- a cherry Coke, a good burger, and a good book are all near the top of the list -- have been well-documented.
Additional Research Links
Harry Browne Permanent Portfolio
High Shareholder Yield Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CL Quantitative Stock Analysis - Warren Buffett

Fintel reports that on October 20, 2025, Raymond James maintained coverage of Colgate-Palmolive (NYSE:CL) with a Outperform recommendation.
Analyst Price Forecast Suggests 22.46% Upside
As of September 29, 2025, the average one-year price target for Colgate-Palmolive is $96.43/share. The forecasts range from a low of $79.79 to a high of $111.30. The average price target represents an increase of 22.46% from its latest reported closing price of $78.74 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Colgate-Palmolive is 19,452MM, a decrease of 2.73%. The projected annual non-GAAP EPS is 3.74.
What is the Fund Sentiment?
There are 2,952 funds or institutions reporting positions in Colgate-Palmolive. This is an decrease of 51 owner(s) or 1.70% in the last quarter. Average portfolio weight of all funds dedicated to CL is 0.28%, an increase of 11.08%. Total shares owned by institutions increased in the last three months by 1.12% to 763,697K shares. The put/call ratio of CL is 0.87, indicating a bullish outlook.
What are Other Shareholders Doing?
Price T Rowe Associates holds 36,548K shares representing 4.52% ownership of the company. In its prior filing, the firm reported owning 34,009K shares , representing an increase of 6.95%. The firm decreased its portfolio allocation in CL by 4.15% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 26,043K shares representing 3.22% ownership of the company. In its prior filing, the firm reported owning 25,630K shares , representing an increase of 1.59%. The firm decreased its portfolio allocation in CL by 12.05% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 23,004K shares representing 2.85% ownership of the company. In its prior filing, the firm reported owning 22,549K shares , representing an increase of 1.98%. The firm decreased its portfolio allocation in CL by 12.08% over the last quarter.
Geode Capital Management holds 20,943K shares representing 2.59% ownership of the company. In its prior filing, the firm reported owning 20,951K shares , representing a decrease of 0.04%. The firm decreased its portfolio allocation in CL by 13.63% over the last quarter.
GQG Partners holds 14,227K shares representing 1.76% ownership of the company. In its prior filing, the firm reported owning 4,296K shares , representing an increase of 69.80%. The firm increased its portfolio allocation in CL by 187.60% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Raymond James Maintains Colgate-Palmolive (CL) Outperform Recommendation

The NASDAQ 100 Pre-Market Indicator is up 125.6 to 24,943.55. The total Pre-Market volume is currently 372,164,591 shares traded.
The following are the most active stocks for the pre-market session:
Replimune Group, Inc. (REPL) is +4.09 at $8.59, with 42,253,588 shares traded. REPL's current last sale is 245.43% of the target price of $3.5.
Rani Therapeutics Holdings, Inc. (RANI) is +0.39 at $2.03, with 33,558,212 shares traded. As reported by Zacks, the current mean recommendation for RANI is in the "strong buy range".
Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.4 at $20.57, with 10,066,687 shares traded. This represents a 227.03% increase from its 52 Week Low.
ProShares UltraPro Short QQQ (SQQQ) is -0.17 at $14.72, with 5,854,775 shares traded., following a 52-week high recorded in prior regular session.
Bitfarms Ltd. (BITF) is +0.36 at $5.37, with 5,423,459 shares traded. As reported by Zacks, the current mean recommendation for BITF is in the "buy range".
New Era Energy & Digital, Inc. (NUAI) is +0.65 at $5.20, with 5,058,145 shares traded.
Archer Aviation Inc. (ACHR) is +0.4 at $11.64, with 2,141,867 shares traded. As reported by Zacks, the current mean recommendation for ACHR is in the "buy range".
NIO Inc. (NIO) is +0.02 at $6.77, with 1,605,273 shares traded. NIO's current last sale is 98.83% of the target price of $6.85.
BigBear.ai, Inc. (BBAI) is +0.21 at $7.63, with 1,314,189 shares traded. BBAI's current last sale is 127.17% of the target price of $6.
IonQ, Inc. (IONQ) is +2.54 at $65.48, with 1,311,808 shares traded., following a 52-week high recorded in prior regular session.
Lithium Americas Corp. (LAC) is +0.34 at $7.13, with 1,281,277 shares traded. LAC's current last sale is 126.19% of the target price of $5.65.
Cleveland-Cliffs Inc. (CLF) is +1.3188 at $14.64, with 1,130,559 shares traded. Smarter Analyst Reports: Cleveland-Cliffs Posts Strong Q3 Results; Shares Pop 4%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Oct 20, 2025 : REPL, RANI, TSLL, SQQQ, BITF, NUAI, ACHR, NIO, BBAI, IONQ, LAC, CLF

Key Points
Weak results from consumer staples companies reflect weakness in the broader economy.
Investing in Dividend Kings is a great way to generate passive income, regardless of how the economy is doing.
Procter & Gamble, Colgate-Palmolive, and Kimberly-Clark are great values, especially in today’s premium-priced market.
The S&P 500 (SNPINDEX: ^GSPC) is having a great year, led by strong gains in tech, communications, financials, and industrials. But not every sector is performing well.
The consumer staples sector is roughly flat year to date. It would be down even more if Walmart, the most valuable stock by market cap in the sector, wasn't outperforming the S&P 500.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Here's what's driving the sell-off in dividend stocks like Procter & Gamble (NYSE: PG), Colgate-Palmolive (NYSE: CL), and Kimberly-Clark (NASDAQ: KMB), and why all three companies are compelling buys in October.
An industrywide downturn
P&G, Colgate-Palmolive, and Kimberly-Clark make household and personal care products for everyday use.
P&G has leading brands in fabric and home care, baby, feminine, and family care, hair care, skin and personal care, grooming, oral care, and personal healthcare.
Colgate-Palmolive is similar to P&G, but it focuses mainly on oral health with its flagship Colgate lineup. It also owns personal care brands like Palmolive, Softsoap, and Speed Stick, home care brands like Ajax and Murphy Oil Soap, Hill's Pet Nutrition, and more.
Kimberly-Clark specializes in products that use paper or absorbent materials, like toilet paper, paper towels, tissues, diapers, adult care, and feminine care.
Consistent demand, paired with international distribution, makes all three companies reliable performers even when economic growth is slow. But the current operating environment is uniquely challenging.
Procter & Gamble CFO Andre Schulten said the following during the company's fourth-quarter fiscal 2025 earnings call:
The volatility the consumer is seeing, is maybe not necessarily grounded in their current reality, but more on what to expect for the future. So consumers are a bit more careful in terms of consumption. They are using up pantry inventory and they are looking for value either in smaller packs and promotions or in larger pack sizes in the club. That's a behavior we've been outlined before, but it's not stopped. It continued. So the trajectory here could be that we've reached the low point and the consumer gains confidence, the labor market is stable, inflation doesn't pick up.
Weak consumer confidence and pullbacks in spending illustrate the conflict between broader stock market gains and the economy. Record spending on artificial intelligence (AI) is occurring as consumers resist inflation and navigate cost-of-living increases. AI spending is benefiting corporations, not consumers.
"I do see purchasing power under pressure, right, for consumers. And frankly, we don't really see a catalyst for that dynamic to change in the near to medium term," said Kimberly-Clark CEO Michael Hsu on the company's second-quarter 2025 earnings call.
"The Colgate-Palmolive team continues to execute with resilience even as the environment remains difficult with category volatility, geopolitical, macroeconomic, and consumer uncertainty, high raw material and packaging costs, including as a result of tariffs and lower levels of end market inflation," said Noel Wallace, CEO of Colgate-Palmolive, on the company's Q2 2025 earnings call.
After years of relying on price increases, consumer goods companies are looking for new ways to pass along value to customers to boost volume. Larger package sizes and multipacks reduce the price per unit of a product, even if they result in lower margins for the manufacturer. Smaller-sized items lower the out-of-pocket expense for people looking to stretch their paychecks.
Three reliable dividend stocks at compelling valuations
P&G, Colgate-Palmolive, and Kimberly-Clark all face slowing revenue growth and stagnating operating margins. Over the last decade, P&G and Colgate-Palmolive have grown sales by less than 25%, while Kimberly-Clark's sales are roughly flat.
P&G and Colgate-Palmolive have high operating margins at 24.2% and 22%, respectively, but there's little room to grow margins due to pricing pressures on consumers, which are spread thin from inflationary pressures. Meanwhile, Kimberly-Clark's operating margins have fallen from high-teens levels pre-pandemic to mid-teens today.
In today's economy, a strong brand will only go so far. The key for these companies is to focus on what they can control by optimizing their supply chains and pricing structure to offset tariff and inflationary effects.
While it's not an easy operating environment for these companies, there's reason for long-term investors to be hopeful. Falling interest rates and trade resolutions should help reduce costs and spur consumer spending. Short-term-focused investors may dump consumer staples stocks in the bargain bin in favor of red-hot AI growth stocks. But if there's a sell-off, it wouldn't be surprising if investors flocked to consumer staples stocks.
At times like this, long-term investors should filter out the noise and focus on fundamentals. P&G, Colgate-Palmolive, and Kimberly-Clark are well-positioned to grow steadily over time and reward investors with consistent passive income.
All three companies are Dividend Kings -- meaning they have raised their dividends for more than 50 consecutive years. In January, Kimberly-Clark made its 53rd consecutive annual raise, followed by Colgate-Palmolive's 63rd raise in March and P&G's 69th consecutive increase in April. The sell-off in all three stocks, paired with consistent dividend raises, pushed Kimberly-Clark's yield up to 4.2%, P&G's yield to 2.8%, and Colgate-Palmolive's yield to 2.7%.
What's more, all three stocks are trading at steep discounts to their historical average valuations.
Best of all, all three companies can easily support their dividends with earnings and free cash flow.
Not only do all three companies have impeccable track records of raising their dividends, they also can afford future dividend raises, even if there's a prolonged period of slower growth due to weak consumer spending.
Power your passive income stream with this regal trio
With growth stocks in the spotlight, long-term investors may want to look backstage at high-quality companies like P&G, Colgate-Palmolive, and Kimberly-Clark that sport compelling valuations, reliable dividends, and high yields.
However, it would be a mistake to expect earnings growth to rebound anytime soon, given the extent of industry challenges.
Should you invest $1,000 in Procter & Gamble right now?
Before you buy stock in Procter & Gamble, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Procter & Gamble wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $646,805!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,113!*
Now, it’s worth noting Stock Advisor’s total average return is 1,055% — a market-crushing outperformance compared to 189% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 13, 2025
Daniel Foelber has positions in Procter & Gamble. The Motley Fool has positions in and recommends Colgate-Palmolive and Walmart. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 High-Yield Dividend King Stocks Down Between 9% and 14% to Buy in October

Key Points
Clorox's operational makeover, paired with an industry-wide downturn, has crushed its stock price.
Efficiency improvements and technological innovations could help the company derive more value from its brands.
Clorox's dividend yield is at a 10-year high.
With the S&P 500 (SNPINDEX: ^GSPC) hovering around an all-time high, investors may be more interested in growth stocks with market-beating potential than high-yield dividend stocks. But long-term investors know that the true value of dividend stocks is the passive income they provide, no matter what the market is doing.
Building a passive income stream is especially useful for investors looking to supplement income in retirement or for folks incorporating passive income into their financial planning.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Here's why Clorox (NYSE: CLX) is an excellent high-yield dividend stock to buy for investors looking to power their passive income stream.
A long overdue recovery
Clorox is in prove-it mode as investors wait to see if its turnaround is the real deal or riddled with overpromises.
Sales and earnings soared during the onset of the COVID-19 pandemic. But Clorox overestimated demand, which crushed its margins. Then came a cyberattack in 2023 that disrupted Clorox's operations and led to product shortages.
As you can see in the chart, it took years for Clorox to recover. And investors lost patience, as Clorox's stock price is now below pre-pandemic levels.
Far from business as usual
Clorox will report its first-quarter fiscal year 2026 results on Nov. 3. Guidance for the fiscal year is weak, as organic sales are expected to decrease between 5% and 9%. Adjusted earnings per share are expected to decline between 18% and 23%. That doesn't sound like a successful turnaround at first glance. But Clorox has already pegged fiscal 2026 as a transition year due to the rollout of its new enterprise resource planning (ERP) system.
Clorox expects the new system to improve internal operations, supply chain, finance, and data management. It will upgrade a decades-old system to a cloud-based platform, which should lower costs and improve efficiency.
But in the near term, the transition is taking a sledgehammer to Clorox's results. To prepare for the transition, Clorox shipped extra product to retailers, which artificially boosted fiscal 2025 sales. With additional inventory, retailers won't need to buy as much from Clorox, which will allow it to execute its ERP transition without letting customers down. A smooth transition is especially important given that Clorox left its retailers hanging during its cyberattack.
Clorox's fiscal 2026 guidance points to a big down year because the ERP transition threw a wrench in retailer order volumes. In its guidance, Clorox said that it expects about an $0.85 to $0.95 impact on adjusted EPS related to the ERP transition. In addition to the impact on retailer inventories, the ERP transition and associated digital technologies are expected to cost $570 million to $580 million in total.
A good time to turn around
Clorox's results are messy because of these one-time investments. But they could pay off long-term, as Clorox clearly needed a tune-up after its blunders during the pandemic and cyberattack.
Pulling forward demand in fiscal 2025 due to the ERP transition may work out in Clorox's favor. The consumer staples sector as a whole is getting hit hard by inflationary pressures and consumers dealing with higher costs of living. The stock prices of leading household and personal care companies, from Procter & Gamble to Colgate-Palmolive, are also hovering around 52-week lows. So now is a great time for Clorox to make long-term investments, even if they disrupt operations.
Clorox has fallen far enough
Clorox is a great buy for investors who don't mind waiting years for its turnaround to play out. Warren Buffett famously said that "You pay a very high price in the stock market for a cheery consensus." But the opposite is true, too. The consensus on Clorox is anything but cheery due to the company's ERP transition and broader industry challenges with consumer demand and economic uncertainty. Long-term investors are getting the chance to buy Clorox for around its lowest level in a decade, which could end up being a bargain if Clorox returns to growth in fiscal 2027.
What's more, Clorox pays an ultra-high-quality dividend. It has increased its payout for 48 consecutive years -- having raised its quarterly payout to $1.24 or $4.96 per year in July. Clorox's languishing stock price, paired with consistent dividend increases, has pushed its yield up to 4.2% -- which is its highest in a decade. The high dividend yield provides a worthwhile incentive for investors to hold the stock while the turnaround plays out.
Time to load up on this passive income powerhouse
Clorox hasn't had a normal year since before the pandemic. And investors are tired of dealing with uncertainty, overpromising, and underdelivering. But fast-forward a year or two, and Clorox could look a lot more appealing. The company has an excellent portfolio of brands, including its flagship Clorox, Burt's Bees, Pine-Sol, Hidden Valley, Brita, and Kingsford.
Clorox doesn't have to acquire new brands. It just needs to get the most out of what it already has. If operational and supply chain improvements accomplish that goal, then Clorox's investment thesis could improve in the coming years.
All told, Clorox is a great contrarian pick for patient investors to buy in October.
Should you invest $1,000 in Clorox right now?
Before you buy stock in Clorox, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Clorox wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $646,805!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,113!*
Now, it’s worth noting Stock Advisor’s total average return is 1,055% — a market-crushing outperformance compared to 188% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 13, 2025
Daniel Foelber has positions in Procter & Gamble. The Motley Fool has positions in and recommends Colgate-Palmolive. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

If I Could Buy Only 1 High-Yield Dividend Stock in October for Passive Income, This Would Be It

The Procter & Gamble Company PG ended fiscal 2025 on a resilient note, navigating a volatile landscape of inflation, tariffs and shifting consumer trends. The consumer goods giant reported fourth-quarter fiscal 2025 core EPS of $1.48, up 6% year over year, and organic sales growth of 2%, driven by balanced contributions from pricing and volume. Growth remained broad-based, with nine of 10 product categories advancing, led by gains in Fabric, Home and Personal Health Care. The company’s consistent execution and cost productivity helped it deliver balanced top and bottom-line growth while returning $16 billion in cash to shareholders.
Looking ahead, fiscal 2026 poses new challenges. Management expects organic sales growth of up to 4% but faces a projected $1-billion tariff headwind that may trim roughly five percentage points from core EPS growth. To offset this, the company plans to leverage productivity gains, pricing actions and innovation-led value creation.
Procter & Gamble’s ongoing two-year restructuring initiative, targeting portfolio simplification, supply-chain optimization and organizational agility, is expected to enhance efficiency and fund innovation investments. Breakthrough launches like Tide evo, a waterless, recyclable detergent and Swiffer PowerMop, the brand’s biggest product debut to date, illustrate PG’s ability to sustain category growth and consumer engagement.
As macro uncertainty persists, the company’s ability to balance pricing power with consumer value perception will determine whether it can sustain steady gains amid the tariff-driven turbulence. With a sharpened focus on superiority, digital capability and market expansion, PG aims to create its tailwinds. The key question for investors: can it maintain its growth momentum amid intensifying tariff and cost pressures?
Tariff Headwinds for PG’s Competitors: CL, CLX & CHD
Tariff pressures are not just a hurdle for Procter & Gamble; rivals like Colgate-Palmolive Company CL, The Clorox Company CLX and Church & Dwight Co., Inc. CHD are also bracing for margin strain as rising trade costs threaten to erode pricing flexibility and supply-chain efficiency across the consumer staples landscape.
Clorox enters fiscal 2026 amid tariff and cost headwinds that threaten to affect its recovery momentum. Despite progress on cost-saving and productivity initiatives, the company faces persistent inflation in manufacturing and logistics, rising promotional spending and ongoing category softness. With ERP-related shipment timing creating a tough comparison and organic sales expected to decline modestly, fiscal 2026 shapes up as a transitional year focused on stabilizing performance and restoring margin strength.
Colgate continues to battle tariff and cost pressures that are straining margins and growth prospects. Persistent raw material inflation, unfavorable currency movements and soft category demand weighed on second-quarter 2025 performance, with the gross margin contracting 70 bps to 60.1%. Despite disciplined cost management and stable pricing, elevated input costs and currency volatility remain key challenges. Year 2025 is shaping up as a period of cautious execution amid macro and tariff-related headwinds.
Church & Dwight faces mounting pressure from tariffs, inflation and slowing category consumption in the U.S. With price hikes largely off the table amid consumer fatigue, the company is absorbing rising input and tariff costs, eroding margins. The gross margin contracted 410 bps in second-quarter 2025, and further compression is expected this year. Despite productivity gains and selective brand investments, 2026 remains a margin-constrained, transition-focused year for CHD.
Zacks Rundown for PG
Procter & Gamble’s shares have lost 3.5% in the past three months compared with the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, PG trades at a forward price-to-earnings ratio of 21.03X, higher than the industry’s 18.7X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Procter & Gamble’s fiscal 2026 and 2027 earnings implies year-over-year growth of 2.2% and 6%, respectively. Earnings estimates for fiscal 2026 and 2027 have been southbound in the past seven days.
PG currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Procter & Gamble Eyes Gains Amid Tariff Turmoil: Can It Deliver?

In trading on Friday, the iShares Global Consumer Staples ETF is outperforming other ETFs, up about 1.3% on the day. Components of that ETF showing particular strength include shares of Kenvue, up about 8.8% and shares of Colgate-palmolive, up about 1.9% on the day.
And underperforming other ETFs today is the Global X Silver Miners ETF, off about 8.1% in Friday afternoon trading. Among components of that ETF with the weakest showing on Friday were shares of New Pacific Metals, lower by about 17%, and shares of Gold Resource, lower by about 14.8% on the day.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.